The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zogopoulos George, Haimi Ido, Sanoba Shenin A, Everett Jessica N, Wang Yifan, Katona Bryson W, Farrell James J, Grossberg Aaron J, Paiella Salvatore, Klute Kelsey A, Bi Yan, Wallace Michael B, Kwon Richard S, Stoffel Elena M, Wadlow Raymond C, Sussman Daniel A, Merchant Nipun B, Permuth Jennifer B, Golan Talia, Raitses-Gurevich Maria, Lowy Andrew M, Liau Joy, Jeter Joanne M, Lindberg James M, Chung Daniel C, Earl Julie, Brentnall Teresa A, Schrader Kasmintan A, Kaul Vivek, Huang Chenchan, Chandarana Hersh, Smerdon Caroline, Graff John J, Kastrinos Fay, Kupfer Sonia S, Lucas Aimee L, Sears Rosalie C, Brand Randall E, Parmigiani Giovanni, Simeone Diane M, PRECEDE Consortium
Аннотация
METHODS: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study. Individuals (aged 18-90 years) are enrolled into 1 of 7 cohorts based on family history and pathogenic germline variant (PGV) status. From April 1, 2020, to November 21, 2022, a total of 3,402 participants were enrolled in 1 of 7 study cohorts, with 1,759 (51.7%) meeting criteria for the highest-risk cohort (Cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound.
RESULTS: A total of 1,400 participants in Cohort 1 (79.6%) had completed baseline imaging and were subclassified into 3 groups based on familial PC (FPC; n=670), a PGV and FPC (PGV+/FPC+; n=115), and a PGV with a pedigree that does not meet FPC criteria (PGV+/FPC-; n=615). One HRI was diagnosed with stage IIB PC on study entry, and 35.1% of HRIs harbored pancreatic cysts. Increasing age (odds ratio, 1.05; P<.001) and FPC group assignment (odds ratio, 1.57; P<.001; relative to PGV+/FPC-) were independent predictors of harboring a pancreatic cyst.
CONCLUSIONS: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV+/FPC+, and PGV+/FPC- risk groups by surveillance protocols.